Send to

Choose Destination
Immunol Res. 2011 Aug;50(2-3):286-93. doi: 10.1007/s12026-011-8211-4.

Immunotherapeutic potential of oncolytic vaccinia virus.

Author information

Department of Surgery and Department of Immunology, University of Pittsburgh Cancer Institute, University of Pittsburgh, 1.46e, Hillman Cancer Center, 5117 Centre Avenue, Pittsburgh, PA 15213, USA.


There has recently been resurgence in interest for the use of replication-selective (oncolytic) viruses for the treatment of cancers. This has been fueled by positive clinical data and the promise provided by next-generation vectors that are better targeted and display enhanced therapeutic potential. One factor that has led to more effective oncolytic vectors has been a greater appreciation of their immunotherapeutic potential. This is especially true for strains of vaccinia virus, where the capability for rapid and destructive spread through a target tissue makes this virus the ideal backbone for an oncolytic agent, while its known ability to produce a potent immune response makes it a powerful immunotherapeutic. Approaches to developing next-generation vectors that are capable of effectively harnessing both of these mechanisms of action are discussed here.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center